Provider Profile

Saint Luke’s Care Member

Provider Profile

Timothy J Pluard, MD

Oncology / Hematology


Medical School
Washington University School of Medicine, St. Louis, MO
Internal Medicine, University of Texas Southwestern Med School, Dallas, TX
Oncology, Dana-Farber Cancer Institute (Harvard Medical School), Boston, MA

Board Certifications

  • American Board of Internal Medicine - Subspecialty in Medical Oncology

Clinical Interests

  • breast cancer (including early-onset cases)
  • neodajuvant therapy of breast cancer
  • general oncology


I joined Saint Luke's Cancer Institute as medical director in August 2013. Previously, I was Associate Professor of Medicine and Clinical Director of Breast Oncology at Washington University/Siteman Cancer Center in St. Louis. I am interested in clinical research studies of new targeted therapies of breast cancer.  The care of women with breast cancer requires a multidisciplinary holistic approach from diagnosis through treatment, recovery, and survivorship. At Saint Luke's Cancer Institute, we have a superb team focused on the comprehensive care of women with breast cancer.

Accepted Insurances

  • Aetna Choice POS II
  • Aetna Choice POS II Aexcel Local
  • Aetna Choice POS II Local
  • Aetna Elect Choice
  • Aetna Federal Employees Health Benefit Plan
  • Aetna HMO
  • Aetna HMO Local
  • Aetna Mail Handlers Benefit Plan
  • Aetna Managed Choice
  • Aetna MDOT & Missouri State Highway Patrol
  • Aetna Medicare
  • Aetna Missouri Preferred
  • Aetna MU myChoice Health Program
  • Aetna Open Choice PPO
  • Aetna Select
  • Aetna Select Local
  • Aetna Signature Administrators (ASA)
  • Aetna Workers Comp
  • BCBS of Kansas (call provider)
  • BCBS of Kansas City (PPO)
  • BCBS of Kansas City Freedom Network
  • BCBS of Kansas City Freedom Network Select
  • BCBS of Kansas City Preferred Care
  • BCBS of Kansas City Preferred Care Blue
  • BCBS of Kansas City Traditional
  • Century Health Solutions (PPO)
  • Cigna (HMO)
  • Cigna (Open Access)
  • Cigna (PPO)
  • CompResults (WC)
  • Coventry Advantra Freedom (PPO)
  • Coventry Health and Life Insurance Company
  • Coventry Health Care
  • Coventry Medicare Advantra (PPO)
  • Golden Rule
  • Health Choice of Northwest Missouri (PPO)
  • Healthcare USA-MC+ (Aetna Better Health)
  • HealthLink (HMO)
  • HealthLink (PPO) through Freedom Network
  • Home State Health Plan (Missouri practices)
  • Humana (PPOx)
  • Humana Choice Care (PPO)
  • Humana Choice PPO (Medicare Advantage PPO)
  • Humana Gold Choice Medicare Advantage PFFS
  • Humana Gold Plus (HMO)
  • Humana Gold Plus HMO SNP
  • Humana SmartExpress PPO
  • Humana SmartNet PPO
  • Humana SmartSuite PPO
  • HumanaOne
  • Integrated Health Plan
  • Kansas Medicaid
  • Medicare
  • Missouri Care (Missouri practices only)
  • Missouri Medicaid
  • MultiPlan/PCHS (PPO)
  • Occupational Health Management (WC)
  • OHARA Managed Care (WC)
  • ProviDRs Care Network (formerly WPPA)
  • Pyramid Life (Medicare Advantage PPO)
  • Railroad Medicare
  • Sunflower State Health Plan (Kansas practices)
  • Triwest Veterans Affairs Patient Centered Community Care
  • United Healthcare Choice
  • United Healthcare Choice Plus
  • United Healthcare Community Plan
  • United Healthcare Definity Health Reimbursement Account
  • United Healthcare Definity Health Savings Account
  • United Healthcare Golden Rule HMO
  • United Healthcare Indemnity
  • United Healthcare Managed Indemnity
  • United Healthcare Options PPO
  • United Healthcare Select
  • United Healthcare Select Plus
  • UnitedHealthcare Evercare DH
  • UnitedHealthcare Evercare DH-POS
  • UnitedHealthcare Evercare DP
  • UnitedHealthcare Evercare RDP
  • UnitedHealthcare Medicare Choice
  • UnitedHealthcare Medicare Choice Essential
  • UnitedHealthcare Medicare Complete
  • UnitedHealthcare Medicare Complete Essential
  • UnitedHealthcare Medicare Complete Plus
  • UnitedHealthcare Medicare DH
  • UnitedHealthcare Medicare Plus Essential
  • US Department of Labor


Peer Reviewed Manuscripts
1. Adkins D, Brown R, Trinkaus K, Maziarz R, Leudke S, Freytes C, Needles B, Fracasso P, Pluard T, Moriconi W, Ryan T, Hoelzer K, Safdar S, Rearden T, Rodriguez G, Khoury H, Vij R, DiPersio J: Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol 17:2006-2014;1999.
2. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM; for the Cancer and Leukemia Group B: A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma. Oncologist. 2010 Dec 10. [Epub ahead of print]
3. Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, AdkinsDR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H., A phase I study of UCN-01 in combination with irinotrecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmocol 2010 Aug 8 [ Epub ahead of print]
4. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K.: Effect of Zoledronic Acid on disseminated tumor cells in women with locally advanced breast cancer: an open label, randomized phase 2 trial. Lancet Oncol May; 11(5):421-8.
5. Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO,Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov;136(2):355-63. doi: 10.1007/s10549-011-1910-7. Epub 2012 Jan 13.
6. Al Mushawah F, Rastelli A, Pluard T, Margenthaler JA. Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ. J Surg Res. 2012 Mar;173(1):10-5. doi: 10.1016/j.jss.2011.04.058. Epub 2011 May 23. PubMed PMID: 21696764.
1. O’Reilly EM, Niedzwiecki D, Hollis DR, Bekaii-Saab TS, Pluard T, Duffy A, Overcash F, Ivy SP, Goldberg RM. A pahse II trial of sunitinib in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol 26:2008 (May 20 suppl; abstr 4515). 
2. T. A. Samuel, C. Sessa, C. Britten, K. S. Milligan, M. M. Mita, U. Banerji, T. J. Pluard, P. Stiegler, C. Quadt, G. Shapiro; A phase I dose escalation study of AUY922, a novel HSP90 inhibitor in patients with advanced solid malignancies. J Clin Oncol 27:15s, 2009 (suppl; abstr 3532)
3. Tan BR, Myerson R, Linehan D, Hawkins W, Pluard T, Fournier C, James J, Strasberg S, Picus J. Adjuvant gemcitabine plus docetaxel followed by 5FU chemoradiation for patients with resected pancreaticobiliary cancers: A single-institution phase II study. ASCO 2008 GastrointestinalCancers Symposium, Abstract No. 237.
4. Hahn OM, Ma CX, Lin L, Sattar H, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard TJ, Watson MA, Ellis M, Conzen SD, Fleming GF: A Phase II Trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer.
SABCS, 2008 Abstract # 407
5. C. Sessa, S. K. Sharma, C. D. Britten, N. J. Vogelzang, K. N. Bhalla, M. M. Mita, T. J. Pluard, P. Stiegler, C. Quadt, G. I. Shapiro; A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. ; J Clin Oncol 27:15s, 2009 (suppl; abstr 3532)
6. Burstein HJ, Barry WT, Cirrincione C, Chew HK, Tolaney S, Lake D, Pluard T, Blackwell K, Winer EP, Hudis CA. CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study; Cancer Research 70(24) 109s
7. Roop R, Naughton M, Schneider J, Lammers P, Pluard T, Johnson F, Eby C, Weilbaecher K. Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients with Metastatic Breast Cancer: A Randomized Phase II Trial. ; Cancer Research 70(24) 250s 
8. Ellis M, Suman V, McCall L, Luo R, Brink A, Watson M, Ma C, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther M, Leitch M, Ota D, Olson J, Hunt K, Allred, C.: Z1031B Neoadjuvant Aromatase Inhibitor Trial: A Phase 2 study of Triage to Chemotherapy based on 2 to 4 week ki67 level >10% Presented at SABCS 2012
Invited Publications
1. Fine HA, Pluard TJ: Tumor angiogenesis: Biology and therapeutic implications In: Mauch P, Loeffler J, (eds.). Radiation Oncology: Theory and Practice.
2. Fehniger T, Welch J, Pluard T. Hematologic Malignancies: Chronic Leukemias. The Washington Manual of Oncology, 2nd edition, 319, 2008.


On Staff At

  • Hedrick Medical Center
  • Saint Luke's East Hospital
  • Saint Luke's Hospital of Kansas City
  • Saint Luke's North Hospital–Barry Road
  • Saint Luke's North Hospital–Smithville
  • Saint Luke's South Hospital